Tag Archives: What is Cdiff?

C Diff Foundation with Leading Gastroenterologist’s Oneto and Feuerstadt Announce November Clinic Dedicated for C.difficile

C Diff Foundation ( https://cdifffoundation.org/)  is a one hundred percent volunteer, world-renowned 501(c)(3) not-for-profit organization and has announced that the Foundation will offer a November clinic sponsored by the C Diff Foundation and dedicated to patients diagnosed and recovering from a C. difficile infection (CDI).

The November 19th C Diff Foundation Clinic will be hosted by Concorde Gastroenterology at their  233 Broadway Suite 840,  New York, NY 10279 office.
The clinic will hold office hours from 10:00 a.m. until  4:00 p.m. ET
With Doctor’s Caterina Oneto, MD and  Paul Feuerstadt, MD

Please call +1 212 889 5544 Ext 199
To schedule an appointment.

The August clinic received an overwhelming response from patients in various stages of recovery, including 15 individuals already scheduled with multiple spots planned for patients with recently diagnosed infection or those who have had multiple episodes and need further guidance and management.

Dr. Oneto said, “Through this clinic, we will provide access to high-level care to a number of new consults, as well as existing patients, who are recovering from the infection. It is my pleasure to partner with the C Diff Foundation and lend my expertise to the management and hopefully, eradication of this debilitating disease.”

“We are delighted with the immediate and overwhelming response from the patient community. It is a testament to the needs of those suffering from this infection. With this clinic, we hope to bring awareness, education and more importantly, cutting edge treatment to the general public,” stated Dr. Feuerstadt.

There are plans for additional clinic dates in 2020  in Florida, New York, Connecticut, Illinois, and Minnesota.

“The clinics demonstrate Doctor Oneto and Feuerstadt’s commitment over the years raising
C. diff. awareness while providing management of those suffering with
a C. diff. infection. Patients who might not otherwise be able to gain access to providers sub-specializing and caring for those with this infection will have this opportunity available.  Doctor’s Oneto and Feuerstadt’s dedication resonates within the C. diff. community and we are grateful for their participation and support.” stated Nancy Caralla, Founding President and Executive Director of the C Diff Foundation.

About C Diff Foundation

C Diff Foundation’s mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, nutrition, diagnostics, and EPA registered products available for environmental safety worldwide.

About Caterina Oneto, MD

Dr. Caterina Oneto, MD is a Gastroenterologist in private practice in New York and is affiliated with NYU Langone. She completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. Dr. Oneto is the Co-Director of Clinical trials at Concorde Medical Group. Her main focus is Irritable Bowel Disease (IBD),

About Paul Feuerstadt, MD

His areas of interest Clostridioides difficile infection (CDI) and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters, and online modules. Another passion of Dr. Feuerstadt is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full-time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

Clostridioides difficile infections (AKA C. diff., C.difficile, CDI) and Microbiome modification.
Dr Oneto is also Co-Director of the C.diff. Community Global Support program offered by the
C Diff Foundation.  Dr. Oneto appears regularly on Doctor Radio on Sirius Xm
and C. diff. Spores and More Radio (cdiffradio.com).

About C.difficile

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare-associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released on February 25, 2015, by the Centers for Disease Control and Prevention (CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

C Diff Foundation Welcomes Dr. Sahil Khanna, M.B.B.S.

We are pleased to welcome Dr. Sahil Khanna
as a Member of the C Diff Foundation and Medical Advisory Board.

Dr. Sahil Khanna is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. He is directing the Comprehensive Gastroenterology Interest group,
C. difficile Clinic, Fecal Microbiota Transplantation program and
C. difficile related Clinical Trials at Mayo Clinic, Rochester, MN.

He completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at University of California San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. He also completed Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations.

Dr. Khanna has over 100 peer-reviewed publications and serves as reviewer and on the editorial board of several journals. He has won numerous awards including the Miles and Shirley Fiterman Award, Mayo Brothers Distinguished Fellowship Award, Donald C. Balfour Mayo Clinic Alumni Association Research Award, Hartz Foundation Young Investigators’ Scholarship and the Most Distinguished Resident Physician Award from the American Association of Physicians of Indian Origin.

C Diff Foundation Announces Appointment of Paul Feuerstadt, M.D., Director of Medical Education

C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Dr. Feuerstadt said, “It is my honor to accept this position. I have been involved with the C Diff Foundation over the last 4.5 years and I look forward to assisting in the continued growth of the organization and ensuring that forward progress, awareness and education increases under my tenure. I look forward to working with the board and volunteers to increase awareness and funding across the country and around the world to highlight this disease through in person events, social media, and in the press.”

Dr. Feuerstadt has spent his career refining his practice and expertise in C. difficile. He is dedicated to educating the public through his work with this organization.

Additionally, he plans to offer free patient and provider education through the launch of his new educational website, EverythingCdifficile.com. The goal of the site is to provide education through short videos with relevant clinical information for educational purposes. The site provides concise 3-5 minute lectures covering core topics, recent publications and major conferences about C. difficile infection to educate both patients and providers.

Nancy C. Caralla, Founding President, C Diff Foundation, commented: “Dr. Feuerstadt is a pre-eminent doctor in this space. His dedication and donation of his time and energy to this worthy cause has helped so many patients to date. We look forward to his enhanced leadership and knowledge as the organization grows and strengthens through our advocacy in
the C.diff. community. Dr. Feuerstadt’s new role as Director of Medical Education will provide an additional avenue of support to patients, families, caregivers, and healthcare providers  through his educational media available on EverythingCdifficile.com. We are grateful for Dr. Feuerstadt’s time and dedication as we continue fighting this debilitating disease worldwide.”

About Dr. Paul Feuerstadt:

His areas of interest Clostridioides difficile infection and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

 

 

May Is National Walking Month and Time For the Annual Global C.diff. (CDI) Awareness 2K Walk

With its fresh Spring mornings and lovely long evenings – not to mention an extra long weekend – it’s no wonder that May is the official National Walking Month. Whether you prefer leisurely strolls or challenging hikes, our four park surroundings have a  walk for everyone to raise awareness of C.diff., walk for a cause in all locations.   Lace up your walking shoes and venture out to Milton A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, PA., Sims Park, New Port Richey, FL.,  on Saturday, May 18th to experience one of  these 3 C.diff. Awareness 2k walks.

 

Registration is open until May 8th.   3rd Annual Global C.diff. Awareness 2K Walks.

The USA events will take place on Saturday, May 18, 2019 from 8 a.m. – 12 p.m.

 

2019 CDIFF Global Awareness Walk

Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.

All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.

Registration is $20.00 per walker and children 10 years of age and under walk free. https://cdifffoundation.org/3rdannualwalk/

Proceeds from the events will benefit the C Diff Foundation’s mission educating and advocating for C.difficile infection prevention, treatments, clinical trials,  environmental safety, sepsis, and antibiotic awareness worldwide.

According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) “has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.”

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient’s gut microbiota. In contrast to fecal transplants or administration of fecal fractions, Vedanta’s medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

Our gratitude to all of the sponsors for their support and partnering with the C Diff Foundation in raising C. diff. awareness worldwide:

Gold Sponsors:    Rebiotix, Pfizer, Ferring Pharmaceutical

Silver Sponsor:    CutisPharma

Bronze Sponsor: Finch Therapeutics

If you have any questions,  please contact one of our staff members at

(727) – 205 – 3922  or e-mail:  info@cdifffoundation.org

We look forward to walking with you on May 18th!

Follow Us On Twitter:   #CdiffWalks2019

Dr. Michael Pride, a Pfizer Scientist, Leads a Team Searching For Ways to Improve Diagnosis, Prevention and Treatment of Clostridium difficile Infections

Dr. Pride of Pfizer leads a team that is searching for ways to improve diagnoses & treatment of C. difficile,

Dr. Michael Pride is the Executive Director, Vaccine Research and Development at Pfizer

Challenges, Chance and Looking Forward. Historically, a difficult diagnosis process has posed challenges to treatment for C. difficile infections, as detection is not straightforward. Dr. Pride and his team are working to tackle this issue by developing better ways to diagnose this infection, which will aid efforts to develop a vaccine. Additionally, he is encouraged by recent work that has demonstrated how an antibody can help prevent recurrent diseases, offering insight that an antibody-mediated response, raised by vaccines, may be a way to help reduce a primary episode of a C. difficile infection.

“If our vaccine is successful, we could help have a great impact on global health, reducing morbidity and even mortality worldwide,” he says. “I’m confident in our team, who is working tirelessly so that hopefully no one must suffer from these horrible symptoms again.”

Today, Dr. Pride leads a team of scientists responsible for the development, qualification and validation of various assays that support Pfizer’s vaccine programs.

 

 

Click on the link below to learn more about Dr. Michael Pride’s Work:

http://innovation.org/about-us/innovation-faces/researcher-profiles/michaelpride?utm_source=Twitter&utm_medium=Social&utm_campaign=NCAC&utm_term=02030501050201&utm_content=DrMichaelPride&sf200705754=1

 

C Diff Foundation ‘Making a Difference’ Award Presented to CutisPharma Inc.

The C Diff Foundation today announced that it presented CutisPharma, Inc., its “Making a Difference” award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

C Diff Foundation

C Diff Foundation’s ‘Making a Difference’ Award Presented at CutisPharma’s Pre-Launch Celebration for Newly Approved C.diff. Drug FIRVANQ

(NEW PORT RICHEY, Fla.) — NEWS: The C Diff Foundation announced today that it presented CutisPharma, Inc., its “Making a Difference” award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

The award was presented at CutisPharma’s celebration of its upcoming launch of FIRVANQ(TM), recently approved by the FDA for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Upon launch, FIRVANQ(TM) will be the only FDA-approved oral vancomycin solution treatment commercially available, improving patient access and reducing pharmacist burden by no longer having to compound oral liquid formulations.

“CutisPharma has been a committed partner of our Foundation and has furthered our mission to increase C.diff. awareness and support the research and development of new treatment options,” said Nancy C. Caralla, Foundress and Executive Director of the C Diff Foundation. “In recognition of CutisPharma’s efforts, we are pleased to grant them the ‘Making a Difference’ award at this special moment in the Company’s 20th anniversary year.”

“We are very grateful to receive such a special distinction from the C Diff Foundation,” said Neal I. Muni, MD, MSPH, and Chief Executive Officer of CutisPharma. “For 20 years, we have been committed to improving the lives of patients who are not well-served by existing therapies and would benefit from high-quality, cost-effective new treatment options. We greatly value our partnership with the C Diff Foundation and look forward to continuing to support their mission.”

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3)non-profit organization, established in 2012, is comprised of 100 percent volunteering professionals dedicated to supporting public health initiatives for C. difficile infection prevention, treatments, environmental safety, and support worldwide. For more information, visit: https://cdifffoundation.org/.

About CutisPharma:

CutisPharma, Inc., based in Wilmington, Mass., is privately held, specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists. CutisPharma’s FIRST(r) Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company’s first FDA-approved Kit, FIRVANQ(TM), will allow significantly broader patient access, convenience to pharmacists and patients alike by reducing the need for compounding, and serve as a potential cost-saving option to existing treatments. For more information, visit: https://cutispharma.com/.

 

Source:   https://enewschannels.com/c-diff-foundation-making-a-difference-award-presented-to-cutispharma-inc/

C. diff. Spores and More, Join Us and Celebrate

www.cdiffradio.com

C. diff. Spores and More

Sponsored by Clorox Healthcare

Join us and Celebrate

with our 81,453 listeners – so far –  in Season III.

We thank our listeners joining us every

Tuesday at 10:00 a.m. PT / 1:00 p.m. ET

across the U.S. A. and to our listeners in

  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • India
  • Ireland
  • Israel
  • Japan
  • Malaysia
  • Peru
  • Russia
  • Spain
  • Switzerland
  • Taiwan
  • Trinidad
  • Ukraine
  • UK    and Across the Globe

We also extend our sincere gratitude to the guests who take time out of their busy

schedules to join us on each live broadcast.  Though their words of wisdom and

by sharing the most up-to-date information with us raises awareness in so

many important areas of healthcare.

 

Season III concludes on October 31, 2017

and we will be gearing up for

the 5th Annual International C. diff. Awareness Conference & Health EXPO taking

place on November 9th and 10th at the University of Nevada – Las Vegas.

For conference information please click on the link below.

https://cdifffoundation.org/2017cdiffconference/about-nov-2017-annual-conference/

 

Join us in Season IV when we return on January 9th, 2018

as we continue bringing you updates that are focused on, but not limited to,

C. difficile infection prevention, treatments, clinical trials, environmental safety

and much more.

Thank you again for listening and we wish you and your families improved health,

continued healing, and the best day — which you all deserve!